A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Guselkumab (Primary)
- Indications Palmoplantar pustulosis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 18 Apr 2017 Planned End Date changed from 1 Jan 2019 to 31 Jan 2019.
- 18 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 31 Jan 2018.
- 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.